Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib

被引：30

作者：

Catalano, Maria Graziella ^{[1
]}

Pugliese, Mariateresa ^{[1
]}

Poli, Roberta ^{[1
]}

Bosco, Ornella ^{[1
]}

Bertieri, Raffaello ^{[2
]}

Fortunati, Nicoletta ^{[3
]}

Boccuzzi, Giuseppe ^{[1
,3
]}

机构：

[1] Univ Turin, Dept Clin Pathophysiol, I-10126 Turin, Italy

[2] Novartis Farma, Dept Med, I-21040 Origgio, Va, Italy

[3] ASO San Giovanni Battista, I-10126 Turin, Italy

来源：

ONCOLOGY REPORTS | 2009年 / 21卷 / 02期

关键词：

anaplastic thyroid cancer; valproic acid; imatinib mesylate; cell cycle; AKT; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR; BCR-ABL; MESYLATE GLEEVEC; APOPTOSIS; STI571; EXPRESSION; THERAPY; P21(CIP1/WAF1); CARCINOMA;

D O I：

10.3892/or_00000252

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

New therapeutic approaches are mandatory for anaplastic thyroid cancer. We investigated the ability of a new combined treatment using valproic acid (VPA), the only clinically available histone deacetylase inhibitor, and the tyrosine-kinase inhibitor imatinib mesylate to control the cell growth of anaplastic thyroid cancer cell lines. We showed that treatment with imatinib alone is unable to affect the cell growth of anaplastic thyroid cancer cells, whereas in ARO cells, the combined treatment resulted in a cytostatic effect, with clinically achievable doses of imatinib and VPA. The effect is mediated by G(1) growth arrest, acting through p21 expression and the impairment of AKT phosphorylation.

引用

页码：515 / 521

页数：7

共 29 条

[1]

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression [J].